April 11, 2022
Adrenomed Gets €7,4M to Develop Covid-19 Drug
Adrenomed AG, the vascular integrity company, has announced that its proprietary sepsis drug candidate Adrecizumab (HAM8101) received a funding commitment of € 7.4 million from the German Federal Ministry of Education and Research (BMBF) as part of the German funding initiatives for the clinical development of COVID-19 drugs and their manufacturing capabilities.